Phase 3 Study of BLU-5937 Shows Promise for Refractory Chronic Cough
A Phase 3 study is underway to evaluate the efficacy and safety of BLU-5937 in adults with refractory chronic cough.
Asset / Drug
Drug and asset intelligence for BLU-5937 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.